Abstract P3-07-07: The updated ASCO/CAP guidelines for HER2 testing create more uncertainty for clinicians

作者
J Chen,Paula Klein,T Shao
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:76 (4_Supplement): P3-07
标识
DOI:10.1158/1538-7445.sabcs15-p3-07-07
摘要

Abstract Background: Accurate assessment of the Human Epidermal Growth Factor Receptor 2 (HER2) status has been an integral part of clinical decision making in treatments of breast cancer. In 2007, American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) published a series of guidelines on how to determine the status of HER2. The guidelines were updated in 2013 with the goal of reducing the numbers of false negative cases. The new guidelines are based on a combination of HER2:CEP17 ratio and average HER2 copy number. We sought to assess the overall effect of the new guidelines. Methods: We retrospectively identified all cases of invasive breast cancer with HER2 testing done in 2014 from the pathology database of Mount Sinai Beth Israel, Mount Sinai St. Luke's and Roosevelt Hospitals. Our pathology department guideline is to perform initial testing for HER2 with immunohistochemistry (IHC) by the HercepTest (Dako) method. Those with IHC of 2+ would be followed by reflex HER2 dual probe FISH. The HER2:CEP 17 ratio and average HER2 copy number were then reviewed for each IHC 2+ case using the 2013 guidelines. These cases were then rescored using the 2007 guidelines. All equivocal cases as determined by the new 2013 guidelines (HER2:CEP17 ratio <2.0 with an average HER2 copy number ≥4.0 and <6.0 signals/cell) were further evaluated to determine whether repeat HER2 testing was performed as suggested by the new guidelines and whether HER2 directed therapy was recommended for patient. Results: Among 853 cases identified in the database, 337 were IHC 2+. Using 2007 guidelines, 27/337 cases (8.0%) were amplified (HER2:CEP 17 ratio >2.2), 6 (1.8%) were equivocal (HER2:CEP 17 ratio 1.8-2.2), and 305 cases (90.2%) were non-amplified (HER2:CEP 17 ratio <1.8). Using the 2013 guidelines, 29/337 cases (8.6%) were amplified (HER2:CEP 17 ratio ≥2 or HER2 copy number ≥6), 23 (6.8%) were equivocal (HER2:CEP17 ratio <2.0 with an average HER2 copy number ≥4.0 and <6.0), and 284 (84.3%) were non-amplified (HER2:CEP 17 ratio <2 with an average HER2 copy number <4.0). The new guidelines resulted in change in HER2 status in 24 cases (7.1%): 2 cases changed from equivocal to amplified, 1 case changed from equivocal to non-amplified, but 20 cases changed from non-amplified to equivocal. Of the 23 equivocal cases determined using the 2013 guidelines, only 13 cases had repeat HER2 analysis. On repeat HER2 testing, one case was found to be HER2 amplified, 4 cases were non-amplified, and 8 cases remained equivocal. Only one equivocal case received HER2 directed treatment. Conclusion: The 2013 ASCO/CAP guidelines for HER2 assessment identified a slightly increased number of patients eligible for HER2 directed therapy, but also resulted in a significant increase in the number of equivocal cases. The new guidelines appear to have generated more uncertainty for the clinician due to the rise in equivocal cases. Further studies are needed to determine whether patients with equivocal HER2 status would benefit from HER2 directed therapy. Citation Format: Chen J, Klein P, Shao T. The updated ASCO/CAP guidelines for HER2 testing create more uncertainty for clinicians. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-07.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
2秒前
2秒前
小无完成签到,获得积分10
2秒前
3秒前
李文英完成签到,获得积分20
3秒前
水煮电吹风的应助被siriuslee99采纳,获得10
3秒前
zy发布了新的文献求助10
4秒前
4秒前
4秒前
sfs完成签到,获得积分0
4秒前
红桶之魂完成签到,获得积分10
4秒前
皮夏寒发布了新的文献求助30
5秒前
5秒前
精明依云发布了新的文献求助10
6秒前
坚定靖柔发布了新的文献求助10
6秒前
金银铜铁铝完成签到,获得积分10
6秒前
MIssing89完成签到,获得积分10
6秒前
7秒前
GUAN完成签到 ,获得积分10
8秒前
8秒前
8秒前
lulu发布了新的文献求助10
8秒前
九号球完成签到,获得积分0
9秒前
秋风的应助被醉熏的寄松采纳,获得10
9秒前
Eason发布了新的文献求助10
9秒前
zzzmss完成签到,获得积分10
10秒前
10秒前
10秒前
风吹麦浪的应助被RUN0221采纳,获得10
10秒前
10秒前
11秒前
香蕉不惜发布了新的文献求助10
11秒前
youxin完成签到,获得积分10
11秒前
搜集达人的应助被lulu采纳,获得10
12秒前
精明依云发布了新的文献求助10
12秒前
13秒前
lml发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621